Replies to post #243945 on Avid Bioservices Inc (CDMO)

[EndoTarget]

Bio, I must admit you were very accurate in your reading finding Debjit C not on the listing of ROTH anymore....

[EndoTarget]

Piper is one of our Market Maker........

[biopharm]

Another interesting twist as Peregrine moves forward. Normally, why would anyone think otherwise about a simple job transfer.... except when it is anyone that has to do with the advancement of Peregrine Pharmaceuticals. We will have to wait and see if PPHM pops up in the Janney shelf

it was easier to lure over Debjit Chattopadhyay and gain any advantage possible with info related to PPHM, especially when Piper Jaffray private clients get an early glimpse of what is hot in biotech

https://www.tipranks.com/analysts/debjit-chattopadhyay

Experience

Managing Director
Janney Montgomery Scott LLC
November 2015 – Present (1 month)

Biotechnology Equity Research
Senior Equity Research Analyst
Roth Capital Partners
April 2014 – November 2015 (1 year 8 months)Greater New York City Area

ROTH Capital Partners | Financing Innovation | Investment Banking, Orange County, CA

..
..
https://www.linkedin.com/in/debjit-chattopadhyay-0247536

EndoTarget, even more interesting.... is now we find out "Roy Buchanan" of Piper Jaffray exits and lands where ?? The same place as Debjit Chattopadhyay ==> Janney !

----------------

Mr. Buchanan covers the biotechnology space from the New York office. Prior to joining Janney, he was a senior associate for three years at Piper Jaffray, where he covered small-to-mid cap biotech companies. Prior to his role at Piper Jaffray, he covered the same space at JMP Securities for two years as an associate. Mr. Buchanan received his Ph.D. in biology from Columbia University in New York and his BS in chemical engineering from the Colorado School of Mines.

http://www.janney.com/institutions--corporations/equities/equity-research/our-team/roy-buchanan-ph-d

---------------

Janney Healthcare Analysts

Roy Buchanan, Ph.D.
Vice President, Biotechnology
212-940-6985

Debjit Chattopadhyay, Ph.D.
Managing Director, Biotechnology
215-665-6224

Paul Knight, CFA
Managing Director, Head of Healthcare Research
212-888-2696

Ken Trbovich, CFA
Director, Specialty Pharmaceuticals
215-665-6290

http://www.janney.com/institutions--corporations/equities/equity-research/our-team

---------------------

For those that want to verify Roy was on some CC's ..

CJ's posts below re: transcripts with Roy Buchanan ( showing up in place of Charles Duncan)


Sept 2014
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106136873&txt2find=roy|buchanan

Dec 2014
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106136873&txt2find=roy|buchanan

March 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111728918&txt2find=roy|buchanan

------------


Why does Janney all of a sudden have interest in two additional healthcare analysts and both happen to cover Peregrine Pharmaceuticals ? Coincidence ....? I do not believe so and I'd even take it as far as Janney was targeting those close to Peregrine and maybe they figure they get some inside scoop of whats to come by picking up Roy and Debjit

"Janney wants in"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118810821&txt2find=janney